Biomarker Discovery Outsourcing Services Market - By Type (Predictive, Prognostic, Safety, Surrogate Endpoints), Service (Genomics, Proteomics, Bioinformatics), Therapeutic Area (Oncology, Cardiology, Cardiovascular), End-use Global Forecast 2024 - 2032

Biomarker Discovery Outsourcing Services Market - By Type (Predictive, Prognostic, Safety, Surrogate Endpoints), Service (Genomics, Proteomics, Bioinformatics), Therapeutic Area (Oncology, Cardiology, Cardiovascular), End-use Global Forecast 2024 - 2032

Biomarker Discovery Outsourcing Services Market Size

Biomarker Discovery Outsourcing Services Market size was valued USD 11.4 billion in 2023 and is estimated to witness 12.7% CAGR from 2024 to 2032. The expansion of the market is propelled by a rising need for personalized medicine, prompting a surge in R&D activities. Also, the need for affordable therapeutic options have driven the demand for precision medicines.
 

For instance, the U.S. Food and Drug Administration (FDA) approved 12 new personalized medicines and expanded the applications of several existing treatments. Similarly, FDA has also authorized two innovative siRNA therapies and provided guidelines for advancing gene & cell-based therapies along with the approved use of five such therapies. Thus, the shift toward personalized medicine is significantly reliant on the identification and validation of biomarkers, thereby augmenting the market growth.
 

Biomarker discovery outsourcing services plays crucial role as a measurable indicator of biological processes or conditions, in disease diagnosis, prognosis, and treatment monitoring. These outsourcing services integrate a range of activities, including sample analysis, data interpretation, and assay development.

COVID-19 Impact

The COVID-19 pandemic has fuelled the growth in the biomarker discovery outsourcing services market. The urgency to develop diagnostic tools, treatments, and vaccines has intensified the demand for biomarker R&D activities. Also, the pandemic has underscored the importance of biomarkers in understanding and managing infectious diseases, pushing pharmaceutical and biotech companies to leverage outsourcing for rapid and effective biomarker discovery. This positive impact is reshaping the landscape, emphasizing the critical role of outsourcing in advancing healthcare solutions amid global health crises.
 

Biomarker Discovery Outsourcing Services Market Trends

• Developing biomarkers is a demanding and resource-intensive undertaking that necessitates expertise in biotechnology, bioinformatic services, and regulatory affairs.
   
• The enhanced focus on cost-effectiveness and resource optimization has driven pharmaceutical and biopharmaceutical firms to increasingly adopt outsourcing services for biomarker discovery. This collaboration was aimed to innovate solution and to streamline the transition from research to clinical application, advancing precision medicine opportunities.
   
• Furthermore, CRISPR-based methodologies and single-cell analysis represent emerging technologies within the realm of biomarker discovery services. These technologies facilitate the swift identification of mutations and provide a more accurate characterization of molecular targets.
   

Biomarker Discovery Outsourcing Services Market Analysis

Based on type, the market is segmented into predictive biomarkers, prognostic biomarkers, safety biomarkers, surrogate endpoints, and other types. The surrogate endpoints are expected to lead the market, projecting the highest revenue of USD 16.2 billion by 2032.
 

• The surrogate biomarkers play a pivotal role in predicting treatment efficacy and safety during drug development. They act as indirect measures representing clinical outcomes.
   
• Also, the reliance on surrogate endpoints streamlines clinical trials by accelerating decision-making and reducing development costs. Thus, the outsourcing services focusing on the identification and validation of surrogate endpoints have become integral, thereby driving the market progress.

Based on service, the biomarker discovery outsourcing services market is classified into genomics biomarker services, proteomics biomarker services, bioinformatics biomarker services, and other services. The genomics biomarker services segment dominated the market accounting for the largest share of 44.4% in 2023.
 

• Genomics biomarker services dominate biomarker discovery outsourcing, leveraging advanced technologies to identify vital biomarkers for precision medicine and drug development.
   
• The precision and depth offered by genomics tools, including next-generation sequencing, empower efficient identification of genetic variations linked to diseases. For instance, in January 2021, Crown Bioscience has enhanced its advanced next-generation sequencing (NGS) capabilities and introduced exclusive NGS panel services. This offers pharmaceutical partners greater insights into drug mechanisms of action, enabling the development of predictive biomarkers. These expanded services aim to enhance accuracy, sensitivity, and speed in advancing new agent programs by uncovering MOAs and predictive biomarkers.
   

Based on therapeutic area, the biomarker discovery outsourcing services market is classified into oncology, cardiology, neurology, autoimmune disease, and other therapeutic areas. The oncology segment is anticipated to grow at CAGR of 11.6% between 2024 and 2032.
 

• Cancer is a major global health concern leading to significant research and investments in oncology biomarkers, driven by the prevalence of diverse types of cancers such as lung, breast, prostate, and colorectal cancers among others.
   
• Therefore, the identification of genomic biomarkers, notably mutations in specific genes such as EGFR, KRAS, and BRCA, holds paramount significance in oncology. Thus, the precision in detecting these cancer biomarkers is facilitated by advanced technologies such as next-generation sequencing and other genomic methodologies. This is expected to influence the management of various cancer types, thereby supplementing the market progress.
   

Based on end-use, the biomarker discovery outsourcing services market is classified into pharmaceutical companies, biotechnology companies, and other end-users. The biotechnology companies dominated the market in 2023 and is expected to show similar trend over the analysis period.
 

• Biotechnology companies collaborate with various CROs to outsource biomarker services, spearheading innovative approaches in biomarker identification and validation. Their specialized expertise and cutting-edge technologies position them as key players, catering to the growing demand for precision medicine solutions.
   
• Pioneering biotech companies shape biomarker-driven drug development, steering the market and strengthening their crucial role in the outsourced biomarker discovery services landscape.

 In 2023, North America held a significant market share in the global biomarker discovery outsourcing services market and is anticipated to dominate the market throughout the forecast period with a CAGR of 12.3%.
 

• North America exerts significant influence over the market, standing as the primary hub for innovative pharmaceutical and biotechnology research.
   
• The region exhibits advanced infrastructure, a robust healthcare ecosystem, and a high concentration of leading outsourcing service providers.
   
• Factors such as strategic collaborations, technological advancements, and substantial investment in research and development further consolidate North America's dominance.
   
• The presence of key players, coupled with a proactive regulatory environment, positions the region as a frontrunner in shaping the trajectory of biomarker discovery outsourcing services globally.
   

Biomarker Discovery Outsourcing Services Market Share

The biomarker outsourcing companies are actively operating in the market, leveraging their research capabilities and global presence. These industry leaders offer diverse services, including target identification, assay development, and clinical trial support, fostering a competitive landscape where innovation, expertise, and global reach are critical differentiators.
 

Biomarker Discovery Outsourcing Services Market Companies

The prominent market players operating in the biomarker discovery outsourcing services industry are as mentioned below

• Bio-Rad Laboratories, Inc.
• Parexel International (MA) Corporation
• Svar Life Science
• Sino Biological, Inc
• ICON plc.
• Integrated DNA Technologies, Inc.
• Almac Group Limited
• REPROCELL Inc. 
• Frontage Labs
• Biomcare ApS
• Crown Bioscience
• RayBiotech, Inc. 
• Excelra
• Evotec
   

Biomarker Discovery Outsourcing Industry News 

• In April 2023, Agilent Technologies Inc. recently signed a Memorandum of Understanding (MOU) with Theragen Bio in South Korea to enhance precision oncology through advanced bioinformatic solutions. The collaboration leverages Agilent's SureSelect Cancer CGP assay and Theragen Bio's localized analysis software to enhance translational research and precision oncology.
   
• In January 2022, Inotiv, Inc. and Synexa Life Sciences revealed their collaboration to advance Inotiv's development of essential biomarkers, enhancing understanding of the safety and efficacy of innovative biotherapeutics. This collaboration enhances the company's preclinical discovery and safety assessment services.
   

The biomarker discovery outsourcing services market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Type, 2018 – 2032 (USD Million)

• Predictive biomarkers
• Prognostic biomarkers
• Safety biomarkers
• Surrogate endpoints
• Other types

By Service, 2018 – 2032 (USD Million)

• Genomic biomarker services
• Proteomics biomarker services
• Bioinformatics biomarker services
• Other biomarker services

By Therapeutic Area, 2018 – 2032 (USD Million)

• Oncology
• Cardiology
• Neurology
• Autoimmune diseases
• Other therapeutic areas

By End-use, 2018 – 2032 (USD Million)

• Pharmaceutical companies
• Biotechnology companies
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa